Boston Scientific Corp. reported the U.S. launch of its Directsense technology, a tool to aid electrophysiologists in measuring tissue response to radiofrequency (RF) waves during cardiac ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback